Evelo Biosciences, Inc. (EVLO): Price and Financial Metrics


Evelo Biosciences, Inc. (EVLO)

Today's Latest Price: $4.12 USD

0.09 (-2.14%)

Updated Jun 4 2:06pm

Add EVLO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

EVLO Daily Price Range
EVLO 52-Week Price Range

EVLO Stock Price Chart More Charts


EVLO Price/Volume Stats

Current price $4.12 52-week high $10.09
Prev. close $4.21 52-week low $3.01
Day low $4.00 Volume 72,945
Day high $4.34 Avg. volume 86,263
50-day MA $4.42 Dividend yield N/A
200-day MA $5.24 Market Cap 133.21M

Evelo Biosciences, Inc. (EVLO) Company Bio


Evelo Biosciences, Inc. focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn’s colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is based in Cambridge, Massachusetts.


EVLO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

EVLO Latest Social Stream


Loading social stream, please wait...

View Full EVLO Social Stream

Latest EVLO News From Around the Web

Below are the latest news stories about Evelo Biosciences Inc that investors may wish to consider to help them evaluate EVLO as an investment opportunity.

Evelo Biosciences, Inc. (EVLO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research | May 29, 2020

Flagship Pioneering Bolsters Executive Team with Appointment of Fabrice Chouraqui in Newly Created Dual Role of Flagship CEO-Partner and CEO of Cellarity

Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.

Yahoo | May 28, 2020

Evelo Biosciences to Present at Jefferies Virtual Healthcare Conference

Evelo Biosciences, Inc. (EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4th at 4:30 p.m. ET. Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. The company’s first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties.

Yahoo | May 28, 2020

Evelo Biosciences Sees Hammer Chart Pattern: Time to Buy?

Evelo Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research | May 27, 2020

Evelo Biosciences, Inc. (EVLO): Hedge Fund Sentiment Unchanged

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]

Yahoo | May 27, 2020

Read More 'EVLO' Stories Here

EVLO Price Returns

1-mo -15.05%
3-mo -17.27%
6-mo -1.44%
1-year -36.81%
3-year N/A
5-year N/A
YTD 1.48%
2019 -68.79%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7352 seconds.